The Journal of infectious diseases · 2024
Antiviral Susceptibility of Highly Pathogenic Avian Influenza A(H5N1) Viruses Circulating Globally in 2022-2023.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Andreev Konstantin, Jones Jeremy C, Seiler Patrick, Kandeil Ahmed, Turner Jasmine C M, Barman Subrata, Rubrum Adam M, Webby Richard J, Govorkova Elena A
Аннотация
The antiviral susceptibility of currently circulating (2022-2023) highly pathogenic avian influenza (HPAI) A(H5N1) viruses was assessed by genotypic and phenotypic approaches. The frequency was low for neuraminidase (NA) and polymerase acidic (PA) substitutions associated with reduced inhibition by NA inhibitors (21/2698, 0.78%) or the PA inhibitor baloxavir (14/2600, 0.54%). Phenotypic testing of 22 clade 2.3.2.1a and 2.3.4.4b viruses revealed broad susceptibility to NA inhibitors and baloxavir for a conclusion that most contemporary HPAI A(H5N1) viruses retain susceptibility to antiviral drugs. Novel NA-K432E and NA-T438I substitutions (N2 numbering) were identified at elevated frequencies (104/2698, 3.85%) and caused reduced zanamivir and peramivir inhibition.
Предметные рубрики MeSH
Antiviral AgentsInfluenza A Virus, H5N1 SubtypeNeuraminidaseAnimalsDrug Resistance, ViralInfluenza in BirdsTriazinesHumansAcids, CarbocyclicDibenzothiepinsMorpholinesPyridonesGuanidinesBirdsInfluenza, HumanZanamivirViral ProteinsRNA-Dependent RNA PolymeraseCyclopentanesGenotypeMicrobial Sensitivity Tests